25 completed, 8 terminated, 2 withdrawn, 1 recruiting. 22 Phase 2, 19 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Completed 15, Terminated 5, Recruiting 1, Withdrawn 1 |
| Phase 1 | 19 | Completed 13, Terminated 5, Unknown 1 |
| Not applicable | 1 | Withdrawn 1 |
| Phase 3 | 1 | Terminated 1 |
Follow this drug Literature Review of STA 9090 trials Research Report on STA 9090
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer Ganetespib, Niraparib, Carboplatin - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | Universitaire Ziekenhuizen KU Leuven | 122 | 2018-11-30 | 2025-06-11 |
| A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer Ganetespib, Paclitaxel, Doxorubicin - Breast Cancer | Not applicable | Withdrawn | University of Chicago | 2016-05-01 | 2016-05-30 | |
| Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer Carboplatin, Ganetespib, Paclitaxel - Gastroesophageal Junction Adenocarcinoma, Malignant Neoplasm of the Cervical Esophagus | Phase 1 | Completed | M.D. Anderson Cancer Center | 3 | 2015-04-10 | 2019-07-24 |
| Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas Ziv-Aflibercept, Ganetespib - Neoplasms | Phase 1 | Terminated | National Cancer Institute (NCI) | 5 | 2014-12-02 | 2018-03-29 |
| Ganetespib Window of Opportunity Study in Head and Neck Cancers Ganetespib, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis - Stage I Hypopharyngeal Squamous Cell Carcinoma, Stage I Laryngeal Squamous Cell Carcinoma | Phase 1 | Terminated | Emory University | 3 | 2014-12-01 | 2016-07-26 |
| A Phase I/II Study of Ganetespib in Combination With Doxorubicin Ganetespib, Doxorubicin - Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Georgetown University | 11 | 2014-10-01 | 2018-04-23 |
| GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer Ganetespib, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1 / Phase 2 | Terminated | Medical University Innsbruck | 133 | 2014-07-04 | 2019-08-13 |
| Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer ganetespib, paclitaxel, trastuzumab - HER2-positive Breast Cancer, Male Breast Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 9 | 2014-04-01 | 2018-06-14 |
| SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) ganetespib, Sirolimus - Malignant Peripheral Nerve Sheath Tumors (MPNST), Sarcoma | Phase 1 / Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 20 | 2013-12-01 | 2019-05-15 |
| Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer paclitaxel, ganetespib, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 / Phase 2 | Terminated | Fox Chase Cancer Center | 12 | 2013-10-09 | 2024-03-26 |
| Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma Ganetespib - Lung Cancer - Malignant Pleural Mesothelioma | Phase 1 / Phase 2 | Completed | University College, London | 27 | 2013-08-01 | 2019-11-13 |
| A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Docetaxel, Ganetespib - Non-Small-Cell Lung Adenocarcinoma, Non-small Cell Lung Cancer Stage IIIB | Phase 3 | Terminated | Synta Pharmaceuticals Corp. | 696 | 2013-04-01 | 2016-07-01 |
| An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer ganetespib - Breast Cancer, HER-2 Positive Breast Cancer | Phase 2 | Completed | Synta Pharmaceuticals Corp. | 51 | 2012-07-01 | 2015-11-05 |
| Fulvestrant With or Without Ganetespib in HR+ Breast Cancer Fulvestrant, Ganetespib - Breast Cancer | Phase 2 | Completed | Dana-Farber Cancer Institute | 50 | 2012-06-01 | 2026-03-03 |
| Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer capecitabine + ganetespib - Rectal Cancer | Phase 1 | Completed | Emory University | 16 | 2012-05-01 | 2016-02-22 |
| Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers Ganetespib (STA-9090) and crizotinib - Advanced Lung Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 13 | 2012-04-16 | 2020-12-30 |
| A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) Ganetespib - Non Small Cell Lung Cancer | Phase 2 | Completed | Synta Pharmaceuticals Corp. | 12 | 2012-04-01 | 2015-05-20 |
| A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma Ganetespib, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 1 | Completed | Emory University | 8 | 2012-01-01 | 2015-10-12 |
| STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma STA-9090 - Melanoma | Phase 2 | Terminated | Dana-Farber Cancer Institute | 3 | 2011-09-01 | 2017-04-12 |
| A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. Plerixafor, AC220, Ganetespib - Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Cardiff University | 113 | 2011-04-01 | 2014-06-11 |
Showing 20 of 37. Sign in to see all of them.
Breast Neoplasms (6) · Neoplasm Metastasis (5) · Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Fallopian Tube Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Carcinoma, Ovarian Epithelial (2) · Leukemia, Myeloid, Acute (2) · Rectal Neoplasms (2) · Sarcoma (2) · Small Cell Lung Carcinoma (2) · Adenocarcinoma (1) · Blast Crisis (1) · Breast Neoplasms, Male (1) · Carcinoma, Hepatocellular (1)
Synta Pharmaceuticals Corp. (10) · Memorial Sloan Kettering Cancer Center (4) · Dana-Farber Cancer Institute (3) · Emory University (3) · Massachusetts General Hospital (2) · Barbara Ann Karmanos Cancer Institute (1) · Cardiff University (1) · David M. Jackman, MD (1) · Fox Chase Cancer Center (1) · Georgetown University (1) · M.D. Anderson Cancer Center (1) · Medical University Innsbruck (1) · National Cancer Institute (NCI) (1) · QuantumLeap Healthcare Collaborative (1) · Sarcoma Alliance for Research through Collaboration (1)
United States (32) · Belgium (4) · United Kingdom (4) · Austria (3) · France (3) · Germany (3) · Canada (2) · Italy (2) · Spain (2) · Argentina (1) · Bosnia and Herzegovina (1) · Brazil (1) · Croatia (1) · Czechia (1) · Hungary (1)
Shanu Modi, MD (2) · AeRang Kim, MD, PhD (1) · Alan K Burnett (1) · Alice P Chen, M.D. (1) · Andrea Cercek, MD (1) · Andrew Zhu, MD (1) · Bassel El-Rayes, MD (1) · Brigitte Widemann, MD (1) · Dana Cardin, MD (1) · David Jackman, MD (1) · Elisabeth Heath (1) · F. Stephen Hodi, M.D. (1) · F. Stephen Hodi, MD (1) · Gina Martina-Smaldone, MD (1) · Giuseppe Giaccone, MD PhD (1)
PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 23530663, PMID 23838996, PMID 25876560, PMID 27406346, PMID 27406347, PMID 28764748, PMID 28851423, PMID 29594044, PMID 29853657, PMID 31898183, PMID 32031889, PMID 32053137, PMID 32089640, PMID 32450725, PMID 32669375, PMID 32701140, PMID 34529000, PMID 34741021, PMID 35623341, PMID 35993306, PMID 36069821, PMID 36456573, PMID 37029329, PMID 37325931, PMID 37505107, PMID 38086377, PMID 38180338, PMID 38745646, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39613746, PMID 39625569, PMID 40526879, PMID 40551254, PMID 40639409, PMID 40679371, PMID 40777112, PMID 41879562, PMID 42530945, PMID 42545411, PMID 42619946, PMID 42811224, PMID 42873573
2017 (1), P30CA006927 (1), P30CA016672 (1)